361 Capital LLC grew its position in Catalent, Inc. (NYSE:CTLT) by 18.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 70,022 shares of the company’s stock after buying an additional 10,974 shares during the quarter. 361 Capital LLC owned approximately 0.06% of Catalent worth $2,795,000 at the end of the most recent quarter.
Other hedge funds also recently bought and sold shares of the company. Acrospire Investment Management LLC boosted its holdings in shares of Catalent by 72.2% during the second quarter. Acrospire Investment Management LLC now owns 3,100 shares of the company’s stock worth $109,000 after purchasing an additional 1,300 shares during the period. Quantbot Technologies LP boosted its holdings in shares of Catalent by 110.7% during the second quarter. Quantbot Technologies LP now owns 3,434 shares of the company’s stock worth $120,000 after purchasing an additional 1,804 shares during the period. Fortaleza Asset Management Inc. acquired a new stake in shares of Catalent during the third quarter worth approximately $164,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Catalent by 12.5% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,043 shares of the company’s stock worth $177,000 after purchasing an additional 559 shares during the period. Finally, Advisor Group Inc. boosted its holdings in shares of Catalent by 1.3% during the second quarter. Advisor Group Inc. now owns 5,185 shares of the company’s stock worth $180,000 after purchasing an additional 65 shares during the period. Institutional investors and hedge funds own 95.65% of the company’s stock.
A number of analysts have issued reports on CTLT shares. Zacks Investment Research cut shares of Catalent from a “buy” rating to a “hold” rating in a research note on Friday, November 3rd. Wells Fargo & Company reiterated an “outperform” rating and issued a $39.00 target price (up from $30.00) on shares of Catalent in a research note on Thursday, August 31st. J P Morgan Chase & Co reiterated a “buy” rating and issued a $40.00 target price on shares of Catalent in a research note on Tuesday, August 29th. Needham & Company LLC reiterated a “hold” rating on shares of Catalent in a research note on Monday, October 23rd. Finally, BidaskClub upgraded shares of Catalent from a “hold” rating to a “buy” rating in a research note on Thursday, October 5th. Five analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $42.11.
Catalent, Inc. (CTLT) traded up $0.10 during trading hours on Thursday, hitting $37.37. 1,082,300 shares of the stock were exchanged, compared to its average volume of 918,991. Catalent, Inc. has a 12 month low of $22.94 and a 12 month high of $43.39. The company has a market capitalization of $4,951.67, a price-to-earnings ratio of 26.06, a price-to-earnings-growth ratio of 2.40 and a beta of 1.49. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.49 and a current ratio of 2.91.
Catalent (NYSE:CTLT) last released its quarterly earnings results on Monday, November 6th. The company reported $0.21 EPS for the quarter, beating the Zacks’ consensus estimate of $0.20 by $0.01. Catalent had a net margin of 5.01% and a return on equity of 23.97%. The company had revenue of $543.90 million for the quarter, compared to analyst estimates of $490.75 million. During the same quarter last year, the firm posted $0.16 earnings per share. The company’s quarterly revenue was up 23.0% compared to the same quarter last year. research analysts expect that Catalent, Inc. will post 1.46 EPS for the current fiscal year.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc. and related companies with MarketBeat.com's FREE daily email newsletter.